Iovance Biotherapeutics files Form 3 for CMO Noah Berkowitz

IOVA•2026-10-02

Iovance Biotherapeutics filed an initial Form 3 beneficial ownership statement for Chief Medical Officer Noah Berkowitz, tied to his Sept. 30, 2026 start date.

1. Ownership filing

Iovance Biotherapeutics filed a Form 3 for Chief Medical Officer Noah Berkowitz tied to his Sept. 30, 2026 start date.

Sources

Iovance Biotherapeutics files Form 3 for CMO Noah Berkowitz

Sec

Iovance Biotherapeutics files Form 3 for CMO Noah Berkowitz

1. Ownership filing

Related News

Professional Diversity Network says Xun Wu will leave CEO role July 22

Safehold enters third amendment to term loan credit agreement with Star Holdings

Shift4 Payments declares $1.50 per share dividend on Series A mandatory convertible preferred stock

Sources

Iovance Biotherapeutics files Form 3 for CMO Noah Berkowitz

Wheeler REIT director Joseph Stilwell disposes of 5 common shares worth $15.15

Grove Collaborative appoints Flip Van Den Bosch as principal financial officer effective October 1